New approach to managing occult hepatitis B infection

I read with great interest the paper by taheri et al. published in (1) hepatitis monthly (number 31, february 2011). the results of this follow-up study are hopeful of hepatitis-b vaccine efficacy in patients who lost hbsag and did not seroconvert to anti-hbs with no detectable hbv dna. however, the editorial in the same issue, as well as taheri et al. themselves, noted some important limitations to this study.